Heartflow (NASDAQ:HTFL) Stock Moved Up to Buy by Wall Street Zen

Wall Street Zen upgraded shares of Heartflow (NASDAQ:HTFL) from a hold rating to a buy rating in a research report released on Sunday morning,Wall Street Zen reports.

Several other research analysts have also issued reports on HTFL. Canaccord Genuity Group upped their target price on Heartflow from $45.00 to $56.00 and gave the company a “buy” rating in a research report on Tuesday, September 22nd. JPMorgan Chase & Co. raised their price target on Heartflow from $35.00 to $45.00 and gave the stock an “overweight” rating in a report on Friday, August 14th. UBS Group assumed coverage on Heartflow in a report on Wednesday, September 9th. They issued a “neutral” rating and a $55.00 price target for the company. Benchmark restated a “buy” rating on shares of Heartflow in a research note on Friday, August 14th. Finally, Piper Sandler restated an “overweight” rating and set a $64.00 price objective (up from $45.00) on shares of Heartflow in a report on Tuesday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $48.62.

Heartflow Price Performance

HTFL opened at $56.71 on Friday. The business has a fifty day moving average of $49.52 and a 200 day moving average of $36.40. The stock has a market cap of $4.93 billion, a P/E ratio of -30.99 and a beta of 2.73. Heartflow has a 52-week low of $20.13 and a 52-week high of $57.74.

Heartflow (NASDAQ:HTFL) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15. The firm had revenue of $64.08 million for the quarter. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%. The business’s quarterly revenue was up 47.7% compared to the same quarter last year. Equities analysts anticipate that Heartflow will post -0.75 EPS for the current fiscal year.

Insider Activity

In other news, insider Campbell Rogers sold 19,682 shares of the company’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $50.15, for a total value of $987,052.30. Following the sale, the insider directly owned 79,956 shares of the company’s stock, valued at $4,009,793.40. This represents a 19.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Vikram Verghese sold 16,766 shares of the stock in a transaction on Friday, September 18th. The stock was sold at an average price of $50.75, for a total transaction of $850,874.50. Following the completion of the sale, the chief financial officer owned 155,183 shares in the company, valued at $7,875,537.25. The trade was a 9.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 304,105 shares of company stock valued at $14,173,800 in the last ninety days. Insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Heartflow

Several hedge funds have recently added to or reduced their stakes in the business. XXEC Inc. purchased a new position in shares of Heartflow during the 2nd quarter valued at about $2,524,764,000. Quantinno Capital Management LP acquired a new position in shares of Heartflow in the 1st quarter valued at about $1,734,000. Sei Investments Co. lifted its holdings in shares of Heartflow by 342.5% in the 1st quarter. Sei Investments Co. now owns 67,048 shares of the company’s stock valued at $1,631,000 after buying an additional 51,895 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of Heartflow in the second quarter worth about $19,096,000. Finally, Handelsbanken Fonder AB purchased a new stake in shares of Heartflow in the second quarter worth about $910,000.

Heartflow Company Profile

Heartflow, Inc is a medical technology company that develops artificial intelligence-based tools to help physicians diagnose and manage coronary artery disease. Its platform uses data from coronary computed tomography angiography (CCTA) scans to create personalized, three-dimensional models of a patient’s coronary arteries and provide noninvasive assessments of blood flow and disease.

The company’s products include Heartflow Analysis, which provides fractional flow reserve computed tomography (FFR-CT) evaluations to help identify potentially significant blockages, as well as tools for assessing coronary plaque and planning treatment.